Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Long-Term Debt Repayments (2022 - 2024)

Eton Pharmaceuticals' Long-Term Debt Repayments history spans 3 years, with the latest figure at $385000.0 for Q3 2024.

  • For Q3 2024, Long-Term Debt Repayments changed 0.0% year-over-year to $385000.0; the TTM value through Jun 2025 reached $385000.0, down 75.0%, while the annual FY2024 figure was $1.2 million, 0.0% changed from the prior year.
  • Long-Term Debt Repayments for Q3 2024 was $385000.0 at Eton Pharmaceuticals, roughly flat from $385000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $385000.0 in Q1 2022 and bottomed at $385000.0 in Q1 2022.
  • The 3-year median for Long-Term Debt Repayments is $385000.0 (2022), against an average of $385000.0.
  • The largest YoY upside for Long-Term Debt Repayments was 0.0% in 2024 against a maximum downside of 0.0% in 2024.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $385000.0 in 2022, then changed by 0.0% to $385000.0 in 2023, then changed by 0.0% to $385000.0 in 2024.
  • Per Business Quant, the three most recent readings for ETON's Long-Term Debt Repayments are $385000.0 (Q3 2024), $385000.0 (Q2 2024), and $385000.0 (Q1 2024).